Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions (LANTERN)

NCT05783323 is registered in ClinicalTrials.gov with Children's Hospital of Philadelphia as lead sponsor.

NCT NCT05783323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05783323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions (LANTERN)
Lead sponsor
Children's Hospital of Philadelphia
Phase
Phase 2
Overall status
Recruiting
Start date
February 14, 2024
Completion date
October 1, 2027
Enrollment
13 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer, thyroid, differentiated thyroid cancer, pediatric cancer